Andrea Pilotto1, Enrico Premi2, Silvia Paola Caminiti2, Luca Presotto2, Rosanna Turrone2, Antonella Alberici2, Barbara Paghera2, Barbara Borroni2, Alessandro Padovani2, Daniela Perani2. 1. From the Neurology Unit, Department of Clinical and Experimental Sciences (A. Pilotto, E.P., R.T., A.A., B.B., A. Padovani), and Nuclear Medicine Unit (B.P.), University of Brescia; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS S.Isidoro Hospital, Trescore Balneario; Neurovascular Unit (E.P.), Brescia Hospital; and Vita-Salute San Raffaele University (S.P.C., D.P.), and Nuclear Medicine Unit, San Raffaele Hospital (L.P., D.P.), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy. pilottoandreae@gmail.com. 2. From the Neurology Unit, Department of Clinical and Experimental Sciences (A. Pilotto, E.P., R.T., A.A., B.B., A. Padovani), and Nuclear Medicine Unit (B.P.), University of Brescia; Parkinson's Disease Rehabilitation Centre (A. Pilotto), FERB ONLUS S.Isidoro Hospital, Trescore Balneario; Neurovascular Unit (E.P.), Brescia Hospital; and Vita-Salute San Raffaele University (S.P.C., D.P.), and Nuclear Medicine Unit, San Raffaele Hospital (L.P., D.P.), Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.
Abstract
OBJECTIVE: To evaluate the statistical parametric mapping (SPM) procedure for fluorodeoxyglucose (FDG)-PET imaging as a possible single-subject marker of progression to dementia in Parkinson disease (PD). METHODS: Fifty-four consecutive patients with PD without dementia (age at onset of 59.9 ± 10.1 years, disease duration of 5.3 ± 3.4 years) entered the study. The patients underwent an extensive motor and cognitive assessment and a single-subject FDG-PET SPM evaluation at baseline. A 4-year follow-up provided disease progression and dementia diagnosis. RESULTS: The FDG-PET SPM was evaluated by 2 expert raters allowing the identification of a "typical PD pattern" in 29 patients, whereas 25 patients presented with "atypical patterns," namely, dementia with Lewy bodies (DLB)-like (n = 12), Alzheimer disease (AD)-like (n = 6), corticobasal syndrome (CBS)-like (n = 5), and frontotemporal dementia (FTD)-like (n = 2). At 4-year follow-up, 13 patients, all showing atypical brain metabolic patterns at baseline, progressed to dementia (PD dementia). The DLB- and AD-like SPM patterns were the best predictor for incident dementia (p < 0.005, sensitivity 85%, specificity 88%), independently from demographics or cognitive baseline classification. CONCLUSIONS: This study suggests that FDG-PET SPM at the single-subject level might help in identifying patients with PD at risk of developing dementia.
OBJECTIVE: To evaluate the statistical parametric mapping (SPM) procedure for fluorodeoxyglucose (FDG)-PET imaging as a possible single-subject marker of progression to dementia in Parkinson disease (PD). METHODS: Fifty-four consecutive patients with PD without dementia (age at onset of 59.9 ± 10.1 years, disease duration of 5.3 ± 3.4 years) entered the study. The patients underwent an extensive motor and cognitive assessment and a single-subject FDG-PET SPM evaluation at baseline. A 4-year follow-up provided disease progression and dementia diagnosis. RESULTS: The FDG-PET SPM was evaluated by 2 expert raters allowing the identification of a "typical PD pattern" in 29 patients, whereas 25 patients presented with "atypical patterns," namely, dementia with Lewy bodies (DLB)-like (n = 12), Alzheimer disease (AD)-like (n = 6), corticobasal syndrome (CBS)-like (n = 5), and frontotemporal dementia (FTD)-like (n = 2). At 4-year follow-up, 13 patients, all showing atypical brain metabolic patterns at baseline, progressed to dementia (PD dementia). The DLB- and AD-like SPM patterns were the best predictor for incident dementia (p < 0.005, sensitivity 85%, specificity 88%), independently from demographics or cognitive baseline classification. CONCLUSIONS: This study suggests that FDG-PET SPM at the single-subject level might help in identifying patients with PD at risk of developing dementia.
Authors: Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat Journal: Dtsch Arztebl Int Date: 2019-11-01 Impact factor: 5.594
Authors: Rosalie V Kogan; Bas A de Jong; Remco J Renken; Sanne K Meles; Paul J H van Snick; Sandeep Golla; Sjoerd Rijnsdorp; Daniela Perani; Klaus L Leenders; Ronald Boellaard Journal: Alzheimers Dement (Amst) Date: 2019-06-22
Authors: Andrea Pilotto; Alberto Romagnolo; Andrea Scalvini; Mario Masellis; Yasushi Shimo; Laura Bonanni; Richard Camicioli; Lily L Wang; Alok K Dwivedi; Katherine Longardner; Federico Rodriguez-Porcel; Mark DiFrancesco; Joaquin A Vizcarra; Elisa Montanaro; Simona Maule; Alessandro Lupini; Carmen Ojeda-López; Sandra E Black; Stefano Delli Pizzi; Myrlene Gee; Ryota Tanaka; Kazuo Yamashiro; Taku Hatano; Barbara Borroni; Roberto Gasparotti; Maria C Rizzetti; Nobutaka Hattori; Leonardo Lopiano; Irene Litvan; Alberto J Espay; Alessandro Padovani; Aristide Merola Journal: Neurology Date: 2021-06-07 Impact factor: 11.800